In the Natural History Database, 44.6% of patients with facial angiofibroma did not receive any treatment for the management of facial angiofibroma, and about one-fourth of patients were treated with off-label, compounded topical mTOR inhibitors for the management of facial angiofibroma. This evidence concerns the gene MTOR and Adenoma sebaceum.